Cosmos Health Earnings & Forecasts

Cosmos Health (COSM) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

분기별 실적 서프라이즈 금액

회계 분기	보고된 날짜	실제 EPS	예상 EPS	놀라다 %
Q2	Aug 18, 2026	$-0.10	$0.01	-1100.0 %
Q1	May 21, 2026	$-0.06	$-0.01	-500.0 %
Q4	Apr 15, 2026	$-0.04	$-0.05	20.0 %
Q4	Apr 16, 2025	$-0.45	$-0.11	-309.1 %

Quarterly Revenue (Billions)

분기별 수익 깜짝 금액

회계 분기	보고된 날짜	실제 수익	예상 수익	놀라다 %
Q2	Aug 18, 2026	$18.99M	$19.42M	-2.24 %
Q1	May 21, 2026	$17.93M	$21.89M	-18.1 %
Q4	Apr 15, 2026	$19.70M	$19.57M	0.66 %
Q4	Apr 16, 2025	$14.22M	$14.50M	-1.90 %

Cosmos Health Guidance

Cosmos Health (COSM)는 9월 3, 2026에 fiscal year 2026에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 범위로 예상했습니다.

이전 가이던스와 비교하여 Cosmos Health는 매출 전망치를 이전 범위인 상향 조정됨에서 $19.4M - $19.4M로 상향 조정했습니다.

Cosmos Health은 10과 9월 18, 2024 사이에 9월 3, 2026개의 지침 업데이트를 발표했습니다. During this period, the company raised its outlook 4 times and lowered it 4 times, providing investors with insight into management's evolving expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q3 '25
Earnings Per Share (Non-GAAP)
Estimate	$0.01	$-0.01	$-0.05	—
Actual	$-0.10	$-0.06	$-0.04	$-0.02
Surprise	-1100.0%	-500.0%	+20.0%	—
Revenue
Estimate	$19.4M	$21.9M	$19.6M	—
Actual	$19.0M	$17.9M	$19.7M	$17.1M
Surprise	-2.24%	-18.1%	+0.66%	—

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$-0.05	$-0.03	$0.01
Revenue
Consensus	$20.9M	$23.0M	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

PRO
Cosmos Health Reaffirms FY 2029 Guidance, Expects $200.60M Revenue, $71.20M Gross Profit, $31M Net Income, $44.20M Adjusted EBITDA

Benzinga Newsdesk

PRO
Cosmos Health Says It Projects Oliv18 To Generate Over $6M In Incremental Annual U.S. Revenue Within 12 To 18 Months

Benzinga Newsdesk

PRO
Cosmos Health Q2 EPS $(0.10) Misses $0.01 Estimate, Sales $18.986M Miss $19.420M Estimate

Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $0.01 by 1100 percent. This is unchanged from the same period last year. The company reported

Benzinga Newsdesk

PRO
Cosmos Health Reports Preliminary Q2 Revenue Of $19.4M, Up 31.5% YoY, H1 Revenue Of $37.3M, Up ~31% YoY

Record Q2 2026 revenue of approximately $19.4 million, up approximately 31.5% year-over-year from $14.75 million in Q2 2025Record first-half 2026 revenue of approximately $37.3 million, up approximately 31% from $28.46

Benzinga Newsdesk

PRO
UPDATE: Cosmos Health Issues Update On U.S. Market Entry Of Its 18 Series Nutraceutical Platform; Projects $22.7M+ Annual U.S. Revenue And $17.0M Gross Profit From 18 Series Nutraceutical Platform At ~75% Margins

Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today provided an update on its United States market entry through the "18 Series," a

Benzinga Newsdesk

PRO
Cosmos Health Q1 EPS $(0.06) Misses $(0.01) Estimate, Sales $17.928M Miss $21.893M Estimate

Cosmos Health (NASDAQ:COSM) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.01) by 500 percent. This is a 100 percent decrease over losses of $(0.03) per share from the

Benzinga Newsdesk

Cosmos Health Inc